Agile Therapeutics Announces Positive Top-line Phase 3 Results
January 03, 2017 16:11 ET
|
Agile Therapeutics, Inc.
Resubmission of Twirla® New Drug Application Expected to Address FDA’s Complete Response LetterCompany Plans to Resubmit NDA in First Half of...
Agile Therapeutics Reports First Quarter 2016 Financial Results
May 09, 2016 16:10 ET
|
Agile Therapeutics, Inc.
Cash Expected to Fund Operations through the End of 2017Clinical Trial Expected to Complete in Fourth Quarter 2016 and Resubmission Planned for First Half 2017 PRINCETON, N.J., May 09, 2016 ...
Agile Therapeutics Appoints Ajit S. Shetty, Ph.D., to Its Board of Directors
February 24, 2016 16:15 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Feb. 24, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX) today announced that Ajit S. Shetty, Ph.D., has been appointed to the Company's Board of Directors,...